FDA Pushback on Accelerated Gene Therapy Approvals

In this episode, Edye Edens dives into the FDA’s evolving scrutiny of accelerated approvals in gene therapy and rare diseases. Using the example of Sarepta’s muscular dystrophy treatment, she explains how postmarket safety issues and incomplete confirmatory trials can put previously celebrated approvals under renewed FDA evaluation.Edye breaks down three common pitfalls sponsors face:Lagging confirmatory trialsOutdated safety monitoring plansPoor communication across teams and with FDAShe offers practical guidance to avoid regulatory setbacks:Build flexible governance frameworksStay proactive with FDA engagementPlan for legal and regulatory risks in confirmatory trialsPrepare for public, regulatory, and payer scrutiny post-approvalAccelerated approval is a major milestone—but it’s not the end. It's the beginning of the next regulatory chapter. Tune in to learn how to manage post-approval responsibilities and secure long-term success for your therapy. Like, comment, or reach out to learn more.Support the show

There are no comments yet.

Please log in to write the first comment.